Oncotelic Therapeutics Inc (OTLC) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oncotelic Therapeutics Inc   (OTLC)


Oncotelic Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Oncotelic Therapeutics Inc's ROI in the second quarter of 2026?
Oncotelic Therapeutics Inc achieved a return on average invested assets (ROI) of 87.35 % in its second quarter of 2026, this is above OTLC's average return on investment of -162.6%.
Oncotelic Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $283 million

ROI fell compared to the first quarter of 2026, despite the net income growth of % from the first quarter of 2026.

Within the Healthcare sector 14 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 30 to 34.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 3772.8 % 2026.73 % 829.72 % -45.25 % -42.18 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 377 374 374 7 6
Return On Investment (TTM) 87.35 % 129.74 % 252.91 % -28.87 % -57.18 %
OTLC's Overall Ranking # 34 # 30 # 29 # 2972 # 3351
Seq. Investment Change TTM 48.6 % 93.47 % 1378.61 % -8.9 % -18.39 %
Seq. Net Income Change TTM 0.05 % -0.75 % - - -
Net Income (TTM) in Millions 247 247 249 -2 -4

OTLC Company Profile >> Back to OTLC Roi Comparisons >> See Annual OTLC Return On Investment



Return On Investment OTLC's Ranking
Within: No.
Industry # 6
Sector # 15
Overall # 34

Return On Investment Statistics
High Average Low
252.91 %
-162.6 %
-4239.83 %
(Dec 31 2025)   (Jun 30 2018)







Financial Statements
Oncotelic Therapeutics Inc's II. Quarter Investments $ 377 Millions OTLC's Balance sheet
Oncotelic Therapeutics Inc's II. Quarter Income $ 0 Millions Quarterly OTLC's Income Statement
OTLC's Income by Division See OTLC's Income by Division


OTLC Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 374 7 13 19 8
Y / Y Investment Growth 5478 % -48.4 % -31.54 % 126.97 % -36.61 %
Net Income in Millions 249 -5 -8 5 -11
Y / Y Net Income Growth - - - - -
Annual Return On Investment 66.6 % -71.3 % -63.17 % 24.64 % -125.79 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 66.6 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
OTLC's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for OTLC's Competitors
Subscribers only: Roi for Oncotelic Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for OTLC's Customers

Other Ratios
OTLC's Roa OTLC's Inventory Turnover Ratio OTLC's Growth Rates OTLC's Dividend Statistics
OTLC's Profitability Ratios OTLC's Asset Turnover Ratio OTLC's Dividend Growth
OTLC's Roe OTLC's Valuation Ratios OTLC's Financial Strength Ratios OTLC's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %

Date modified: 2026-09-26T07:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.